Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
May 2014, Vol 5, No 4
May 2014, Vol 5, No 4
Multitargeted Kinase Inhibitor Shows Promise for Breast Cancer Subgroup
By
Charles Bankhead
AACR Annual Meeting
May 2014, Vol 5, No 4
San Diego, CA—A multitargeted kinase inhibitor met criteria for a phase 3 clinical trial in breast cancer after statistical modeling of clinical data showed a high probability of success versus standard therapy for patients with HER2-positive/hormone receptor (HR)-negative (HER2+/HR–) disease.
Read Article
Highest Response in Metastatic Renal-Cell Carcinoma with Pazopanib, Third-Line VEGF Inhibitor
By
Charles Bankhead
AACR Annual Meeting
May 2014, Vol 5, No 4
San Diego, CA—Almost 50% of patients with metastatic renal-cell carcinoma (mRCC) had objective responses to third-line treatment with the angiogenesis inhibitor pazopanib, according to the results of a small clinical trial reported at the 2014 American Association for Cancer Research annual meeting.
Read Article
Potential New Approach to Melanoma
By
Phoebe Starr
AACR Annual Meeting
May 2014, Vol 5, No 4
San Diego, CA—Preliminary results suggest that an investigational antibody-drug conjugate called DEDN-6526A (Seattle Genetics, Genentech) has activity against melanoma, including cutaneous, mucosal, and ocular melanoma, which is considered difficult to treat. The new drug comes on the heels of trastuzumab emtansine, the first antibody-drug conjugate approved by the US Food and Drug Administration for the treatment of breast cancer.
Read Article
Payers Facing Multiple Challenges in Ensuring Access to Cancer Care
By
Wayne Kuznar
May 2014, Vol 5, No 4
Los Angeles, CA—The cost of cancer care is a major cost driver for payers, who are actively engaging in the management of this complex disease state. Payer approaches to cancer care continue to evolve, with new reimbursement methodologies key to maintaining affordability, said Gary M. Owens, MD, President, Gary Owens Associates, Ocean View, DE, and John Fox, MD, MHA, Senior Medical Director and Associate Vice President of Medical Affairs, Priority Health, Grand Rapids, MI, at the Fourth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Frequent Mammography Screening for Breast Cancer Adds Billions to Cost
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
May 2014, Vol 5, No 4
The total annual cost of mammography screening for women aged 40 to 85 years in the United States is estimated to be $7.8 billion, according to a new analysis (O’Donoghue C, et al.
Ann Intern Med
. 2014;160:145-153). That is $4.3 billion more than the cost would be if mammography intervals were lowered to fall in line with the recommendations of the US Preventive Services Task Force (USPSTF), the study researchers calculated.
Read Article
Value Propositions
Economics & Value
,
Value Peer-spectives
May 2014, Vol 5, No 4
Value Propositions for May 2014.
Read Article
Zykadia Approved for Metastatic, ALK-Positive Lung Cancer
FDA Approvals, News & Updates
,
In the News
May 2014, Vol 5, No 4
The US Food and Drug Administration (FDA) approved ceritinib (Zykadia; Novartis) for the treatment of patients with metastatic, anaplastic lymphoma kinase (ALK)-positive non–small-cell lung cancer (NSCLC). Ceritinib is an ALK tyrosine kinase inhibitor that blocks proteins that promote cancer cell growth. The drug is approved for the treatment of patients with late-stage NSCLC who were previously treated with crizotinib, the first and only other ALK tyrosine kinase inhibitor approved by the FDA.
Read Article
The Affordable Care Act and Two-Tiered Cancer Care: Is This a Bad Thing?
By
Craig Deligdish, MD
From the Editor
,
Value Peer-spectives
May 2014, Vol 5, No 4
Defining and improving quality and outcomes in the care of patients with cancer is difficult, so it is interesting that we are now having a dialogue regarding the potential for a two-tiered healthcare system. Can we really define second-class cancer care if we have difficulty grading, measuring, identifying, or even defining first-class cancer care?
Read Article
AG-221 Achieved Excellent Responses in Relapsed, Refractory Leukemia, Myelodysplastic Syndrome
By
Phoebe Starr
AACR Annual Meeting
May 2014, Vol 5, No 4
San Diego, CA—Preliminary data suggest that a novel agent called AG-221 can induce complete remissions (CRs) in patients with relapsed, refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who harbor mutated
IDH2
. These exciting results were achieved in patients with an ominous prognosis who have few or no other treatment options. The data were presented at the 2014 American Association for Cancer Research (AACR) annual meeting.
Read Article
Challenges Facing US Cancer Care in 2014: ASCO’s First Annual Report to the Nation
By
Eileen Koutnik-Fotopoulos
Economics & Value
,
Economics of Cancer Care
May 2014, Vol 5, No 4
Advances in cancer treatment, from detection and diagnosis to drugs, surgical techniques, and new imaging capabilities, have collectively enabled many patients to live longer, healthier lives with or after cancer. However, a new landmark report, “The State of Cancer Care in America, 2014: A Report by the American Society of Clinical Oncology” (ASCO), identifies the many challenges that will impact the future delivery of cancer care (ASCO.
J Oncol Pract
. 2014;10:119-143). These challenges include an increasing demand for care, predicted workforce shortages, rapidly rising costs, imbalances in access to care, and an unstable practice environment.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma